MIRAE, Canada

Registration Status: Completed

Objective: The purpose of the MIRAE Biobank is to facilitate future on cancer immunotherapies and traditional autoimmune and autoinflammatory diseases. Cancer immunotherapy refers to various treatments that enhance the power of human immune cells to seek out and destroy cancer cells. These treatments can lead to remarkable cancer remissions, but their use is sometimes limited by significant autoimmune toxicities. The goal of the study is to answer questions such as why some patients taking a cancer immunotherapy develop immune side effects while others do not, and what are the immune mechanisms responsible for these side effects during treatment. Answering these questions will lead to the development of more personalized treatment for patients with cancer requiring immunotherapy in the future. By comparing patients with immune side effects from immunotherapy with patients with traditional autoimmune and autoinflammatory diseases, we also seek to gain novel insights into naturally occurring autoimmune diseases.

Registered Biobank Name MIRAE
Biobank Leader Christel Dias
Country Canada
Email for biobank inquiries marie.hudson@mcgill.ca
Principal Investigator Dr Marie Hudson
User Type
  • Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties
  • Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group
  • Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper
Biospecimen Collected: